Vaccines can be a cost effective preventive measure for both primary prevention of disease and prevention of disease recurrence. Several vaccines targeting breast cancer oncodrivers are currently being tested in clinical trials. Whereas clinical response rates to breast cancer vaccines have been modest despite the induction of strong antitumor T cell responses, it is through these approaches that valuable insight and knowledge have been gained about tumor immunology. With the emergence of new immunotherapies, there is renewed excitement for effective breast cancer vaccine development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2019.02.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!